GALT · Insider Trading
Galectin Therapeutics Inc.
Every open-market purchase and sale reported by GALT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Richard E Uihlein | Director | M | +34,376,167 | +$105.81M |
| 2026-07-16 | Khurram Jamil | Chief Medical Officer | MIXED | — | −$33.88K |
| 2026-06-25 | Khurram Jamil | Chief Medical Officer | MIXED | — | −$14.43K |
| 2026-05-28 | Khurram Jamil | Chief Medical Officer | MIXED | — | −$1.06K |
| 2026-03-17 | Henry Brem | Director | A | +60,000 deriv. | — |
| 2026-02-09 | Kary Eldred | Director | Buy | +300 | +$810 |
| 2026-01-22 | Joel Lewis | President and CEO | A | +91,000 deriv. | — |
| 2026-01-21 | Elissa J. Schwartz | Director | A | +60,000 deriv. | — |
| 2026-01-21 | Kary Eldred | Director | A | +60,000 deriv. | — |
| 2026-01-21 | Benjamin Carson Sr | Director | A | +60,000 deriv. | — |
| 2026-01-21 | Gilbert S Omenn | Director | A | +60,000 deriv. | — |
| 2026-01-21 | Kevin D Freeman | Director | A | +60,000 deriv. | — |
| 2026-01-21 | Gilbert F Amelio | Director | A | +60,000 deriv. | — |
| 2026-01-21 | Richard A. Zordani Jr. | Director | A | +60,000 deriv. | — |
| 2026-01-21 | Joel Lewis | President and CEO | A | +204,000 deriv. | — |
| 2026-01-21 | Jack W Callicutt | Chief Financial Officer | A | +165,000 deriv. | — |
| 2026-01-21 | Richard E Uihlein | Director | A | +13,158 | +$40.00K |
| 2026-01-21 | Harold H. Shlevin | Director | A | +60,000 deriv. | — |
| 2026-01-21 | Khurram Jamil | Chief Medical Officer | A | +165,000 deriv. | — |
| 2026-01-13 | Joel Lewis | President and CEO | — | −56,332 | −$218.57K |
| 2026-01-06 | Khurram Jamil | Chief Medical Officer | MIXED | — | −$232.40K |
| 2026-01-06 | Joel Lewis | President and CEO | MIXED | — | −$321.13K |
| 2026-01-06 | Jack W Callicutt | Chief Financial Officer | MIXED | — | −$233.39K |
| 2026-01-05 | Khurram Jamil | Chief Medical Officer | MIXED | — | −$23.10K |
| 2025-12-23 | Kary Eldred | Director | Buy | +700 | +$2.61K |
| 2025-12-23 | Kevin D Freeman | Director | Buy | +5,500 | +$19.51K |
| 2025-12-23 | Kevin D Freeman | Director | Buy | +5,500 | +$19.51K |
| 2025-12-23 | Kary Eldred | Director | Buy | +700 | +$2.61K |
| 2025-12-23 | Kevin D Freeman | Director | Buy | +5,500 | +$19.51K |
| 2025-12-19 | Joel Lewis | President and CEO | MIXED | — | −$32.85K |
| 2025-12-19 | Khurram Jamil | Chief Medical Officer | MIXED | −4,479 | −$101.40K |
| 2025-12-19 | Harold H. Shlevin | Director | MIXED | −4,499 | −$132.82K |
| 2025-12-18 | 10X Fund, L.P. | 10%+ Owner | MIXED | −164,043 | −$613.01K |
| 2025-12-16 | Harold H. Shlevin | Director | MIXED | — | −$59.85K |
| 2025-12-10 | Harold H. Shlevin | Director | MIXED | −4,000 | −$664.51K |
| 2025-12-08 | 10X Fund, L.P. | 10%+ Owner | Sell | −486,207 | −$2.76M |
| 2025-12-04 | 10X Capital Management, LLC | 10%+ Owner | Sell | −450,000 | −$2.56M |
| 2025-11-19 | Jack W Callicutt | Chief Financial Officer | MIXED | — | −$359.29K |
| 2025-11-19 | Joel Lewis | President and CEO | MIXED | — | −$82.68K |
| 2025-11-14 | Khurram Jamil | Chief Medical Officer | MIXED | +19,633 | −$220.47K |
| 2025-11-12 | James C Czirr | 10%+ Owner | Sell | −120,000 | −$630.00K |
| 2025-11-12 | Joel Lewis | President and CEO | MIXED | — | −$6.79K |
| 2025-11-12 | Jack W Callicutt | Chief Financial Officer | MIXED | — | −$24.17K |
| 2025-11-07 | Joel Lewis | President and CEO | MIXED | — | −$722 |
| 2025-11-07 | Jack W Callicutt | Chief Financial Officer | MIXED | +400 | −$238 |
| 2025-11-05 | Joel Lewis | President and CEO | MIXED | — | −$57.77K |
| 2025-11-05 | Jack W Callicutt | Chief Financial Officer | MIXED | — | −$144.47K |
| 2025-10-24 | James C Czirr | 10%+ Owner | Sell | −150,000 | −$740.40K |
| 2025-09-15 | Joel Lewis | President and CEO | MIXED | — | −$55.59K |
| 2025-09-15 | Jack W Callicutt | Chief Financial Officer | MIXED | — | −$44.13K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Richard E Uihlein | Director | 55,046,519 | $175.60M |
| James C Czirr | Director | 11,758,091 | $37.51M |
| 10X Fund, L.P. | 10%+ Owner | 8,370,399 | $26.70M |
| 10X Capital Management, LLC | 10%+ Owner | 5,802,207 | $18.51M |
| Joel Lewis | President and CEO | 778,260 | $2.48M |
| Kevin D Freeman | Director | 135,269 | $431.51K |
| Kary Eldred | Director | 67,682 | $215.91K |
| Gilbert S Omenn | Director | 66,769 | $212.99K |
| Gilbert F Amelio | Director | 60,614 | $193.36K |
| Richard A. Zordani Jr. | Director | 44,083 | $140.62K |
| Khurram Jamil | Chief Medical Officer | 16,250 | $51.84K |
| Marc Rubin | Director | 13,581 | $43.32K |
| Jack W Callicutt | Chief Financial Officer | 7,614 | $24.29K |
| Harold H. Shlevin | Director | 6,500 | $20.73K |
| Elissa J. Schwartz | Director | 1,000 | $3.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GALT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.